Clinical trials: Lung Cancer Metastatic
Malignant Neoplasm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog…
- Trial name
- NCT07252739
- Testing
- MK-1084, Pembrolizumab, Cetuximab
- Where
- 39 sites in United States, Chile and 11 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- FLAURA (NCT02296125)
- Testing
- Erlotinib 150/100 mg, Gefitinib 250 mg
- Where
- 170 sites in United States, Australia and 28 more
- Volunteers
- 674 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Malignant Neoplasm, PET/CT
Integrin αvβ6-targeted PET in Malignant Tumors
Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment.
- Conditions
- Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic
- Trial name
- NCT05835570
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongnan Hospital
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
This open-label, non-randomized, one-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show…
- Trial name
- NCT01609543
- Testing
- erlotinib [Tarceva]
- Where
- 23 sites in Hungary, Latvia and 1 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Circulating Tumor Cells
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients
- Trial name
- NCT01052818
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- National Institute of Cancerología
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive…
- Trial name
- SUMMIT (NCT01953926)
- Testing
- Neratinib, Fulvestrant, Trastuzumab
- Where
- 60 sites in United States, Australia and 11 more
- Volunteers
- 582 people
- Sponsor
- Puma Biotechnology, Inc.
Non-small Cell Lung Cancer Metastatic
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
The goal of this interventional study is to learn about the combination of sotorasib and stereotactic radiation therapy (SBRT) in patients with metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutations.
- Trial name
- K-SAB (NCT06127940)
- Testing
- Stereotactic body radiation therapy (SBRT), Temporary Stopping
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska University Hospital
Non Small Cell Lung Cancer
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor…
- Trial name
- WU-KONG36 (NCT06195189)
- Testing
- Sunvozertinib, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed.
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant
- Trial name
- NCT05375825
- Testing
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC)…
- Trial name
- Checkmate 171 (NCT02409368)
- Testing
- Nivolumab
- Where
- 90 sites in Austria, Denmark and 11 more
- Volunteers
- 812 people
- Sponsor
- Bristol-Myers Squibb
Leptomeningeal Metastasis From Lung Cancer
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
This is a phase I/II, single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, and preliminary efficacy of intrathecal injection of methotrexate-loaded autologous tumor cell-derived…
- Trial name
- NCT07559097
- Testing
- Methotrexate-loaded vesicles
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
- Trial name
- NCT02580708
- Testing
- Rociletinib, Trametinib
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Clovis Oncology, Inc.
Non-Small Cell Lung Cancer
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or…
- Trial name
- NCT07362940
- Testing
- GEN-725 tablets + Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 110 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
NSCLC (Non-small Cell Lung Cancer)
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
- Trial name
- KANNON (NCT06015503)
- Testing
- PLB1004
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.
- Trial name
- ELIOS (NCT03239340)
- Testing
- Osimertinib
- Where
- 26 sites in United States, Italy and 3 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca